Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. promoterapy

PromoTeRapy SIGNED

Haploinsufficiency and Intractable Epilepsy Rescue Increasing Endogenous Gene PromoterEfficiency

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 PromoTeRapy project word cloud

Explore the words cloud of the PromoTeRapy project. It provides you a very rough idea of what is the project "PromoTeRapy" about.

expression    excitability    integrating    treatment    combine    functional    promoters    reprogramming    fibroblast    scn1a    mouse    patients    genetics    excitatory    exogenous    haploinsufficency    models    expertise    full    neurosciences    mechanistic    crispr    techniques    regulate    nav1    unparalleled    untranslated    neurology    fibroblasts    model    tool    clinical    network    knca1    biophysics    disorders    gene    leads    neurophysiology    resource    regulatory    neuronal    risks    epilepsy    international    syndrome    interneurons    treat    molecular    encodes    health    insights    ucl    channel    endogenous    focal    sodium    burdens    genetically    epileptic    tools    variants    first    opportunity    sequences    strategy    insertional    biology    exploits    genetic    therapeutic    intractable    neurons    collaborators    mutagenesis    create    therapy    kv1    haploinsufficiency    genes    genome    panoply    rescue    splice    severe    epilepsies    multidisciplinary    dravet    underlies   

Project "PromoTeRapy" data sheet

The following table provides information about the project.

Coordinator		 UNIVERSITY COLLEGE LONDON 

Organization address
address: GOWER STREET
city: London
postcode: WC1E 6BT
website: http://www.ucl.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Total cost 195˙454 €
 EC max contribution 195˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2018-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (London) coordinator 195˙454.00

Map

 Project objective

This proposal will develop a new tool to rescue haploinsufficiency, which underlies many genetic disorders of neuronal excitability, and provide a new approach to treatment of intractable epilepsy. This new tool is based on the CRISPR-On technology which can regulate the expression of endogenous genes by directly targeting their promoters, which allows expression of the full panoply of splice variants and untranslated regulatory sequences. Importantly, the method does not require integrating exogenous genes into the genome, which has potential risks of insertional mutagenesis. Haploinsufficency of SCN1A, which encodes the sodium channel Nav1.1, leads to Dravet Syndrome, a severe epilepsy. My first aim is to increase SCN1A gene expression in interneurons derived by reprogramming fibroblasts obtained from Dravet Syndrome patients. I will then determine whether this strategy can be effective in non-genetic epilepsies by applying CRISPR-On technology to increase KNCA1(Kv1.1) expression in excitatory neurons in a mouse model of focal epilepsy. This project will combine my previous experience with functional analysis of neurons in different epileptic models; an unparalleled resource of genetically-characterized patients, a well characterized model of intractable epilepsy, and gene therapy techniques at the UCL Institute of Neurology; and expertise on the CRISPR-On method and fibroblast reprogramming of international collaborators. Epilepsy is one of the most important health burdens within the clinical neurosciences, and finding tools that open new mechanistic and therapeutic insights is a high priority. My proposal exploits an opportunity to establish a new tool to treat epileptic disorders and to create an international multidisciplinary network including neurophysiology, clinical neurology, molecular biology, biophysics and genetics.

 Publications

year authors and title journal last update
List of publications.
2017 Gareth Morris, Marco Leite, Dimitri M. Kullmann, Ivan Pavlov, Stephanie Schorge, Gabriele Lignani
Activity Clamp Provides Insights into Paradoxical Effects of the Anti-Seizure Drug Carbamazepine
published pages: 5484-5495, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.3697-16.2017 		The Journal of Neuroscience 37/22 2019-06-14

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROMOTERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROMOTERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More  

DEF2DEV (2019)

Identification of the mode of action of plant defensins during root development and plant defense responses.

Read More  

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More